BioTime Starts US-China Test of Cancer Diagnostic
January 29, 2014 at 08:30 AM EST
BioTime, a California stem cell company, has begun a concurrent study of its bladder cancer diagnostic test in the US and China. OncoCyte, Biotime’s cancer-focused subsidiary, will compare standard-of-care diagnostic technologies (cellular microscopic analysis of the urine samples) to OncoCyte's PanC-Dx™ biomarkers for relative efficacy. OncoCyte has identified the PanC-Dx biomarkers as being abnormally activated in cancer or tumor cells, many of which were not previously associated with cancer. More details.... Stock Symbol: (NYSE: BTX) Share this with colleagues: // //